Foresee Pharmaceuticals Co., Ltd. (6576) Stock Statistics & Valuation Metrics
Total Valuation
Foresee Pharmaceuticals Co., Ltd. has a market cap or net worth of TWD 11.33B. The enterprise value is TWD 12.17B.
- Market Cap
- TWD 11.33B
- Enterprise Value
- TWD 12.17B
Share Statistics
Foresee Pharmaceuticals Co., Ltd. has 157,540,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 157,540,540
- Owned by Insiders
- ―
- Owned by Institutions
- 1.88%
Financial Efficiency
Foresee Pharmaceuticals Co., Ltd.’s return on equity (ROE) is -0.95 and return on invested capital (ROIC) is -69.81%.
- Return on Equity (ROE)
- -0.95
- Return on Assets (ROA)
- -0.67
- Return on Invested Capital (ROIC)
- -69.81%
- Return on Capital Employed (ROCE)
- -0.84
- Revenue Per Employee
- 245.04K
- Profits Per Employee
- -501.79K
- Employee Count
- 1,760
- Asset Turnover
- 0.33
- Inventory Turnover
- 0.95
Valuation Ratios
The current PE Ratio of Foresee Pharmaceuticals Co., Ltd. is 527.86. Foresee Pharmaceuticals Co., Ltd.’s PEG ratio is 1.07.
- PE Ratio
- 527.86
- PS Ratio
- 24.71
- PB Ratio
- 9.07
- Price to FCF
- -19.41
- Price to Operating Cash Flow
- -21.17
- PEG Ratio
- 1.07
Income Statement
In the last 12 months, Foresee Pharmaceuticals Co., Ltd. had revenue of 431.27M and earned -883.15M in profits. Earnings per share was -5.70.
- Revenue
- 431.27M
- Gross Profit
- 294.22M
- Operating Income
- -862.32M
- Pretax Income
- -858.20M
- Net Income
- -883.15M
- EBITDA
- -784.50M
- Earnings Per Share (EPS)
- -5.70
Cash Flow
In the last 12 months, operating cash flow was -545.15M and capital expenditures -54.71M, giving a free cash flow of -599.86M billion.
- Operating Cash Flow
- -545.15M
- Free Cash Flow
- -599.86M
- Free Cash Flow per Share
- -3.84
Dividends & Yields
Foresee Pharmaceuticals Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.15%
- Earnings Yield
- 0.19%
Stock Price Statistics
- Beta
- 0.41
- 52-Week Price Change
- -6.87%
- 50-Day Moving Average
- 78.70
- 200-Day Moving Average
- 79.84
- Relative Strength Index (RSI)
- 26.17
- Average Volume (3m)
- 120.19K
Important Dates
Foresee Pharmaceuticals Co., Ltd. upcoming earnings date is Mar 12, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- Mar 12, 2027
- Ex-Dividend Date
- ―
Financial Position
Foresee Pharmaceuticals Co., Ltd. as a current ratio of 3.44, with Debt / Equity ratio of 24.93%
- Current Ratio
- 3.44
- Quick Ratio
- 2.94
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- 0.32
- Interest Coverage Ratio
- -154.90
Taxes
In the past 12 months, Foresee Pharmaceuticals Co., Ltd. has paid 24.95M in taxes.
- Income Tax
- 24.95M
- Effective Tax Rate
- -0.03
Enterprise Valuation
Foresee Pharmaceuticals Co., Ltd. EV to EBITDA ratio is -25.65, with an EV/FCF ratio of -18.61.
- EV to Sales
- 23.69
- EV to EBITDA
- -25.65
- EV to Free Cash Flow
- -18.61
- EV to Operating Cash Flow
- -20.48
Balance Sheet
Foresee Pharmaceuticals Co., Ltd. has TWD 910.92M in cash and marketable securities with TWD 398.33M in debt, giving a net cash position of TWD 512.58M billion.
- Cash & Marketable Securities
- TWD 910.92M
- Total Debt
- TWD 398.33M
- Net Cash
- TWD 512.58M
- Net Cash Per Share
- TWD 3.25
- Tangible Book Value Per Share
- TWD 7.50
Margins
Gross margin is 22.10%, with operating margin of -104.50%, and net profit margin of 4.77%.
- Gross Margin
- 22.10%
- Operating Margin
- -104.50%
- Pretax Margin
- 18.94%
- Net Profit Margin
- 4.77%
- EBITDA Margin
- -92.38%
- EBIT Margin
- -101.13%
Analyst Forecast
The average price target for Foresee Pharmaceuticals Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 6.41%
- EPS Growth Forecast
- ―
